Emma S. Rennel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emma S. Rennel has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- David Owen Bates
University of Nottingham
4 shared publications Steven J. Harper
Microvascular Research Laboratories, Bristol Heart Institute, School of Physiology and Pharmacology, Veterinary Sciences Building, University of Bristol, Bristol, UK
2 shared publicationsA J Churchill
Bristol Eye Hospital Lower Maudlin St, Bristol BS1, UK
1 shared publication- Alexander H. R. Varey
Melanoma Institute Australia, The University of Sydney, Sydney, Australia
1 shared publication Anette Magnussen
Microvascular Research Laboratories, Department of Physiology and Pharmacology, School of Veterinary Science, University of Bristol, Southwell Street, Bristol BS2 8EJ, United Kingdom
1 shared publication- Christian Klein
Faculty for Chemistry and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
1 shared publication
Latest Publications
- 18 August 2011
- Published by Wiley in Microcirculation
- Vol. 18 (7) , 598-607
A Human Neutralizing Antibody Specific to Ang‐2 Inhibits Ocular Angiogenesis
Please cite this paper as: Rennel, Regula, Harper, Thomas, Klein and Bates (2011). A Human Neutralizing Antibody Specific to Ang-2 Inhibits Ocular Angiogenesis. Microcirculation 18(7), 598–607. Abstract Objective: Angiogenesis, a critical contributor to ocular as well as neoplastic diseases, is stimulated by endothelial production of angiopoietin-2 (Ang2). Our objective was to determine the requirement of ocular angiogenesis for Ang2 in animal models of disease. Methods: We developed and compared the effect of a novel human Ang2 antibody with a pan-angiopoietin strategy on angiogenesis in ocular angiogenesis in animal models of oxygen-induced retinopathy, and laser photocoagulation and confirmed its efficacy in xenografted human colorectal tumors. Results: Human anti-Ang2 and anti-angiopoietin1(Ang1)/Ang2 antibodies blocked colorectal carcinoma growth in immuno-compromised mice (p < 0.001, n = 6). Injection of 1 μg of Ang2 or Ang2/Ang1 antibody-inhibited angiogenesis in models of retinal (p < 0.001, n = 6), and choroidal neovascularization (p < 0.001, n = 11–13 per group) to levels similar to that with anti-VEGF antibodies. There was no difference between Ang2 specific and Ang1/Ang2 bi-specific antibodies. In vitro, Ang2 antibodies showed no cytotoxicity and did not inhibit endothelial cell migration or proliferation. Conclusion: Thus, human Ang2 antibodies are potentially therapeutic agents for ocular neovascularization in models of retinal and choroidal neovascularization, in the absence of VEGF inhibition.
- 18 August 2011
- Published by Wiley in Microcirculation
- Vol. 18 (7) , 598-607
A Human Neutralizing Antibody Specific to Ang‐2 Inhibits Ocular Angiogenesis
Please cite this paper as: Rennel, Regula, Harper, Thomas, Klein and Bates (2011). A Human Neutralizing Antibody Specific to Ang-2 Inhibits Ocular Angiogenesis. Microcirculation 18(7), 598–607. Abstract Objective: Angiogenesis, a critical contributor to ocular as well as neoplastic diseases, is stimulated by endothelial production of angiopoietin-2 (Ang2). Our objective was to determine the requirement of ocular angiogenesis for Ang2 in animal models of disease. Methods: We developed and compared the effect of a novel human Ang2 antibody with a pan-angiopoietin strategy on angiogenesis in ocular angiogenesis in animal models of oxygen-induced retinopathy, and laser photocoagulation and confirmed its efficacy in xenografted human colorectal tumors. Results: Human anti-Ang2 and anti-angiopoietin1(Ang1)/Ang2 antibodies blocked colorectal carcinoma growth in immuno-compromised mice (p < 0.001, n = 6). Injection of 1 μg of Ang2 or Ang2/Ang1 antibody-inhibited angiogenesis in models of retinal (p < 0.001, n = 6), and choroidal neovascularization (p < 0.001, n = 11–13 per group) to levels similar to that with anti-VEGF antibodies. There was no difference between Ang2 specific and Ang1/Ang2 bi-specific antibodies. In vitro, Ang2 antibodies showed no cytotoxicity and did not inhibit endothelial cell migration or proliferation. Conclusion: Thus, human Ang2 antibodies are potentially therapeutic agents for ocular neovascularization in models of retinal and choroidal neovascularization, in the absence of VEGF inhibition.
- Open Access
- 25 August 2009
- Published by Springer Nature in British Journal of Cancer
- Vol. 101 (7) , 1183-1193
VEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo
The key mediator of new vessel formation in cancer and other diseases is VEGF-A. VEGF-A exists as alternatively spliced isoforms - the pro-angiogenic VEGFxxx family generated by exon 8 proximal splicing, and a sister family, termed VEGFxxxb, exemplified by VEGF165b, generated by distal splicing of exon 8. However, it is unknown whether this anti-angiogenic property of VEGF165b is a general property of the VEGFxxxb family of isoforms. The mRNA and protein expression of VEGF121b was studied in human tissue. The effect of VEGF121b was analysed by saturation binding to VEGF receptors, endothelial migration, apoptosis, xenograft tumour growth, pre-retinal neovascularisation and imaging of biodistribution in tumour-bearing mice with radioactive VEGF121b. The existence of VEGF121b was confirmed in normal human tissues. VEGF121b binds both VEGF receptors with similar affinity as other VEGF isoforms, but inhibits endothelial cell migration and is cytoprotective to endothelial cells through VEGFR-2 activation. Administration of VEGF121b normalised retinal vasculature by reducing both angiogenesis and ischaemia. VEGF121b reduced the growth of xenografted human colon tumours in association with reduced microvascular density, and an intravenous bolus of VEGF121b is taken up into colon tumour xenografts. Here we identify a second member of the family, VEGF121b, with similar properties to those of VEGF165b, and underline the importance of the six amino acids of exon 8b in the anti-angiogenic activity of the VEGFxxxb isoforms.
- 25 August 2009
- Published by Springer Nature in British Journal of Cancer
- Vol. 101 (7) , 1183-1193
Open AccessVEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo
The key mediator of new vessel formation in cancer and other diseases is VEGF-A. VEGF-A exists as alternatively spliced isoforms - the pro-angiogenic VEGFxxx family generated by exon 8 proximal splicing, and a sister family, termed VEGFxxxb, exemplified by VEGF165b, generated by distal splicing of exon 8. However, it is unknown whether this anti-angiogenic property of VEGF165b is a general property of the VEGFxxxb family of isoforms. The mRNA and protein expression of VEGF121b was studied in human tissue. The effect of VEGF121b was analysed by saturation binding to VEGF receptors, endothelial migration, apoptosis, xenograft tumour growth, pre-retinal neovascularisation and imaging of biodistribution in tumour-bearing mice with radioactive VEGF121b. The existence of VEGF121b was confirmed in normal human tissues. VEGF121b binds both VEGF receptors with similar affinity as other VEGF isoforms, but inhibits endothelial cell migration and is cytoprotective to endothelial cells through VEGFR-2 activation. Administration of VEGF121b normalised retinal vasculature by reducing both angiogenesis and ischaemia. VEGF121b reduced the growth of xenografted human colon tumours in association with reduced microvascular density, and an intravenous bolus of VEGF121b is taken up into colon tumour xenografts. Here we identify a second member of the family, VEGF121b, with similar properties to those of VEGF165b, and underline the importance of the six amino acids of exon 8b in the anti-angiogenic activity of the VEGFxxxb isoforms.
- 11 June 2009
- Published by Taylor & Francis in Future Oncology
- Vol. 5 (5) , 703-712
Therapeutic Potential of Manipulating VEGF Splice Isoforms in Oncology
Anti-angiogenic therapies currently revolve around targeting vascular endothelial growth factor-A (VEGF-A) or its receptors. These therapies are effective to some degree, but have low response rates and poor side-effect profiles. Part of these problems is likely to be due to their lack of specificity between pro- and anti-angiogenic isoforms, and their nonspecific effects on proactive, pleiotropic survival and maintenance roles of VEGF-A in endothelial and other cell types. An alternative approach, and one which has recently been shown to be effective in animal models of neovascularization in the eye, is to target the mechanisms by which the cell generates pro-angiogenic splice forms of VEGF-A, its receptors and, co-incidentally, by targeting the upstream processes, other oncogenes that have antagonistic splice isoforms. The concept here is to target the splicing mechanisms that control splice site choice in the VEGF-A mRNA. Recent evidence on the pharmacological possibilities of such splice factors is de...
- 11 June 2009
- Published by Taylor & Francis in Future Oncology
- Vol. 5 (5) , 703-712
Therapeutic Potential of Manipulating VEGF Splice Isoforms in Oncology
Anti-angiogenic therapies currently revolve around targeting vascular endothelial growth factor-A (VEGF-A) or its receptors. These therapies are effective to some degree, but have low response rates and poor side-effect profiles. Part of these problems is likely to be due to their lack of specificity between pro- and anti-angiogenic isoforms, and their nonspecific effects on proactive, pleiotropic survival and maintenance roles of VEGF-A in endothelial and other cell types. An alternative approach, and one which has recently been shown to be effective in animal models of neovascularization in the eye, is to target the mechanisms by which the cell generates pro-angiogenic splice forms of VEGF-A, its receptors and, co-incidentally, by targeting the upstream processes, other oncogenes that have antagonistic splice isoforms. The concept here is to target the splicing mechanisms that control splice site choice in the VEGF-A mRNA. Recent evidence on the pharmacological possibilities of such splice factors is de...
- 1 September 2008
- Published by Elsevier in European Journal of Cancer
- Vol. 44 (13) , 1883-1894
Recombinant human VEGF165b protein is an effective anti-cancer agent in mice
- 1 September 2008
- Published by Elsevier in European Journal of Cancer
- Vol. 44 (13) , 1883-1894
Recombinant human VEGF165b protein is an effective anti-cancer agent in mice